Several studies indicate that activation and dysregulation of the serine/threonine kinase mammalian target of rapamycin (mTOR) are associated with tumorigenesis but also processes like tumor growth, metastasis, and drug resistance in various tumor entities (Popova and Jücker 2021). Here, MARK2 is linked to neoplasm.